Reading the Semaglutide SmPC: What It Contains and Why It Matters

What the SmPC actually contains, and why it is written for clinicians

A Summary of Product Characteristics is a legal document. The MHRA approves every word of it as part of the licensing process, and prescribers and pharmacists are expected to consult it when making clinical decisions. The Wegovy SmPC sets out the medicine's licensed indications (weight management for adults with a BMI of 30 or above, or 27 and above with at least one weight-related condition), its contraindications, the approved dosing schedule from 0.25mg upward to 2.4mg or 7.2mg maintenance, and the full safety data gathered across the clinical trial programme. If you want to read it directly, the eMC (the electronic Medicines Compendium) hosts every current UK SmPC and is publicly accessible. Find the Wegovy entry, note the version date, and you are looking at the same document your prescriber references. That version-date check takes about thirty seconds and tells you whether the copy you found elsewhere online is current.

It is dense reading. The pharmacokinetics section, for example, covers absorption rates and half-life data that are clinically relevant but rarely something a patient needs to act on directly. The sections most people find genuinely useful are Section 4.3 (contraindications), Section 4.4 (special warnings), Section 4.6 (fertility, pregnancy and lactation) and Section 4.8 (undesirable effects). Bring your questions about those sections to your prescriber rather than drawing conclusions from them alone.

What the SmPC says about indications, and what Wegovy is not licensed for

This is the section where the SmPC and everyday online conversation diverge most sharply. The Wegovy SmPC covers weight management. Ozempic (also semaglutide) has its own SmPC, for type 2 diabetes. The two documents are not interchangeable, and the MHRA is clear that Ozempic is not licensed for weight loss. If you are researching semaglutide for weight management, Wegovy is the correct product and its SmPC is the correct document. Rybelsus (oral semaglutide, 3mg, 7mg and 14mg tablets) holds a third, separate licence for type 2 diabetes, and if you are looking into the Wegovy tablet schedule you can read about semaglutide 1 as a starting point for understanding where the dose journey begins. Getting the right SmPC matters because the licensed indications, eligible populations and safety warnings are product-specific.

The NHS patient-level overview of semaglutide on NHS.uk translates the key SmPC sections into plain language and is a good companion read alongside the formal document. It is not a substitute for the SmPC for clinical purposes, but it makes the core safety messages far more accessible.

Contraindications, pregnancy, and the conversations the SmPC prompts

Section 4.3 of the Wegovy SmPC lists absolute contraindications, conditions where the medicine must not be used. A personal or family history of medullary thyroid carcinoma, and the rare inherited condition Multiple Endocrine Neoplasia syndrome type 2 (MEN2), are among them. Section 4.4 covers situations requiring particular care, including a history of pancreatitis. Section 4.6 is unambiguous: semaglutide is not recommended during pregnancy, breastfeeding, or while actively trying to conceive. Women of childbearing age should use effective contraception during treatment; for women on oral contraceptives, the guidance for tirzepatide specifically requires an additional non-oral method during the early weeks, while the evidence for semaglutide in this respect differs, your prescriber can clarify which applies to your situation. Our clinical team has a page on who shouldn't take semaglutide that walks through these exclusions in plain terms.

None of this replaces a proper clinical assessment. The SmPC gives a prescriber the framework; the prescriber applies it to your history. That is precisely why semaglutide is a prescription-only medicine.

Side effects, dose escalation, and what the SmPC frames as normal

Section 4.8 of the Wegovy SmPC documents undesirable effects by frequency category. The most common are gastrointestinal: nausea, constipation, diarrhoea, vomiting and reflux appear in the clinical trial data at rates that the SmPC labels as very common or common. They tend to be most noticeable in the first weeks of treatment or after a dose step, and the reason the approved schedule starts at 0.25mg is specifically to let the body adjust before the dose rises. The SmPC does not tell you to push through discomfort regardless, it notes that dose escalation should be guided by tolerability, and that is a clinical conversation, not a self-managed decision. If you want to understand how the middle stages of that titration are structured, our pages covering semaglutide 2 and semaglutide 3 explain what those dose steps involve in practice. If you are exploring how Wegovy works in practice, that interplay between titration and side-effect management is worth understanding before you start.

One SmPC entry that is easy to overlook is the guidance on reporting. The UK's Yellow Card scheme at yellowcard.mhra.gov.uk allows patients and clinicians to report suspected side effects directly to the MHRA, and that reporting is part of what keeps the SmPC current after a medicine is licensed. Wegovy carries a Black Triangle (▼) designation, meaning it is subject to additional MHRA monitoring, the SmPC will be updated if the post-market safety picture changes. If you are thinking about starting treatment and want to discuss what the SmPC means for your individual circumstances, the right step is a consultation with a prescriber who can read it in the context of your medical history. You can find more on weight management treatment options or, if you are ready, speak to our prescribers through a free consultation.